- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00814827
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
Mycobacterial and Opportunistic Infections in HIV-Negative Patients Associated With Autoantibodies to Interferon-gamma
Opportunistic infections are caused by bacteria, mycobacteria, fungi or viruses that do not normally cause infections in people with healthy immune systems. Some of these infections can cause public health concerns, especially in areas with limited access to treatment. People who acquire opportunistic infections usually have diseases that affect their immune systems, such as human immunodeficiency virus (HIV), or do not have enough white blood cells to fight the infection. However, some people acquire opportunistic infections even though they have normal amounts of white blood cells and are free from known diseases that harm their immune systems. This study will investigate some of the reasons that otherwise healthy people get opportunistic infections to learn more about why some people are more likely to have them.
This study will include up to 210 HIV-negative males and females older than 18 years of age who have opportunistic infections. The patients will be drawn from multiple sites in Thailand and Taiwan including Khon Kaen University Hospital, Siriraj Hospital, Ramathibodi Hospital, National Taiwan University Hospital, National Cheng-Kung University Hospital
Patients will undergo an initial evaluation that will include a physical examination, medical history, and blood and urine testing. Additional tests will be conducted if the researchers consider that the tests are medically necessary to treat the opportunistic infection; the results of the tests will be reviewed and saved for study purposes. Depending on the severity of the infection, the initial evaluation may take more than 1 day to complete.
After the evaluation, patients will be given standard and appropriate medicines to treat the infections.
Patients will return for follow-up visits to allow researchers to monitor their condition and to assess how well the patient is responding to the treatment. Patients will be evaluated by the study researchers at least once a year for 2 years following the initial treatment.
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
- INCLUSION CRITERIA:
Patients must meet all of the following criteria at the time of evaluation to be eligible for enrollment into the study cohorts:
Group 1 (NTM alone):
- Past or current infection with NTM proven by culture or specific DNA detection in the presence of a compatible clinical picture as judged by the responsible clinician and PI on site.
- NTM is not felt to iatrogenic (such as indwelling catheter associated or post-operative wound infection)
- HIV negative within 3 months either prior to the diagnosis of OI, or prior to enrollment in this study, if HIV status was unknown at the time of OI
- No evidence of active malignancy
- No systemic corticosteroids at time of diagnosis of OI (defined as greater than 4 weeks at a dose greater than 10 mg per day of prednisone within 3 months prior to diagnosis of the NTM)
- No preexisting immune deficiency
Group 2 (non-NTM OI with or without NTM):
- Patients must have or have had proven infection with one or more of the following organisms: disseminated Salmonella, Listeria, Penicillium, Burkholderia pseudomallei, Cryptococcus, Histoplasma, Herpes zoster involving 2 or more non-contiguous dermatomes, or extradermal involvement or other opportunistic infections not listed above, but relevant, as determined by the PI.
- Patient may have infection with NTM in addition to one or more of the above infection(s).
- HIV-negative within 3 months either prior to the diagnosis of OI, or prior to enrollment in this study, if HIV status was unknown at the time of OI diagnosis
- No evidence of active malignancy
- No systemic corticosteroids at time of diagnosis of OI (defined as greater than 4 weeks at a dose greater than 10 mg per day of prednisone within 3 months prior to diagnosis of the NTM)
- No preexisting immune deficiency
Group 3 (diseased control with pulmonary MTB):
- Active pulmonary MTB, i.e. patients who have sputum that is either culture positive for MTB or AFB positive and responding to therapy for MTB.
- Diagnosed with the past 6 months.
- No concurrent infections due to NTM or OI listed under above inclusion criteria for study subjects
- No clinical evidence of HIV
Group 4 (diseased control with disseminated MTB):
Disseminated MTB includes infections involving greater than or equal to 2 noncontiguous sites, one of which may include pulmonary disease or greater than or equal to 2 separate groups of lymph nodes.
- Active disseminated MTB or cured disseminated MTB
- No concurrent infections due to NTM or OI listed under above inclusion criteria for study subjects
- HIV negative within 3 months either prior to the diagnosis of MTB, or prior to enrollment in this study, if HIV status was unknown at the time of MTB diagnosis
- No evidence of active malignancy
- No systemic corticosteroids at time of diagnosis of OI (defined as > 4 weeks at a dose > 10 mg per day of prednisone within 3 months prior to diagnosis of the NTM)
- No preexisting immune deficiency.
Group 5 (Blood Specimen Donors):
Eligibility criteria not applicable. Blood will be collected from volunteers, and no medical evaluation will be performed.
To be a blood donor the person cannot be excluded per the exclusionary criteria:
- Patient < 18 or > 85
- Weight > 45 kg (99 lbs)
- Receiving chemotherapy of have cancer
- Receiving immunosuppressant medications
- Have a history of heart, lung, kidney disease of bleeding disorder.
EXCLUSION CRITERIA:
Patients will be excluded for the following reasons:
- HIV-positive serostatus for groups 1, 2 and 4 (groups 3 and 5 will not be routinely performing HIV testing)
- Active malignancy
- Medical conditions requiring immune modulating therapy (i.e. corticosteroids, biological agents, anti-metabolites) and /or chemotherapy
- Any other medical conditions unsuitable for this study as determined by the principal investigator
- Age less than 18 years
- Receiving any other investigational study agents when enrolling on this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Group 1
Patients with nontuberculous mycobacteria (NTM) alone.
|
Group 2
Patients with non-NTM opportunistic infection, either with or without concurrent NTM infection.
|
Group 3
Patients with pulmonary mycobacterium tuberculosis (MTB).
|
Group 4
Patients with disseminated mycobacterium tuberculosis (MTB).
|
Group 5
Blood Specimen Donors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of the presence of autoantibodies to IFNy in HIV-negative Thai and Taiwanese patients with disseminated NTM and OI who are followed at the participating institutions.
Time Frame: ongoing
|
Compare the baseline prevalence rate of autoantibodies to IFNg, as defined by having >75% inhibition, in patients with disseminated NTM or other OI (groups 1 and 2) versus normal or diseased controls (groups 3 and 5).
|
ongoing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of predisposing factors for the development of autoimmunity to cytokines and/or their receptors.
Time Frame: ongoing
|
Identification of predisposing factors for the development of autoimmunity to cytokines and/or their receptors.
|
ongoing
|
Identification of other autoantibodies that might manifest similarly to patients with autoantibodies to IFNg.
Time Frame: ongoing
|
Identification of other autoantibodies.
|
ongoing
|
Characterization of the natural history and specific microbiology in HIV-negative patients with disseminated NTM and other OI and to determine any statistically significant differences from MTB controls or healthy blood bank donors.
Time Frame: ongoing
|
Characterization of the natural history and infections of consecutive patients with NTM alone and NTM with other OI.
Speciation of the opportunistic infections identified and categorization of these infections with descriptive statistics.
|
ongoing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christa S Zerbe, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publications and helpful links
General Publications
- Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000 Dec;11(4):321-33. doi: 10.1016/s1359-6101(00)00010-1.
- Patel SY, Ding L, Brown MR, Lantz L, Gay T, Cohen S, Martyak LA, Kubak B, Holland SM. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol. 2005 Oct 1;175(7):4769-76. doi: 10.4049/jimmunol.175.7.4769.
- Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S, Nicol M, Scholvinck E, Relman D, Waddell S, Langford P, Sheehan B, Semple L, Wilkinson KA, Wilkinson RJ, Ress S, Hibberd M, Levin M. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest. 2005 Sep;115(9):2480-8. doi: 10.1172/JCI19316. Epub 2005 Aug 25.
- Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, Kirk JL, Jutivorakool K, Zaman R, Ding L, Hsu AP, Patel SY, Olivier KN, Lulitanond V, Mootsikapun P, Anunnatsiri S, Angkasekwinai N, Sathapatayavongs B, Hsueh PR, Shieh CC, Brown MR, Thongnoppakhun W, Claypool R, Sampaio EP, Thepthai C, Waywa D, Dacombe C, Reizes Y, Zelazny AM, Saleeb P, Rosen LB, Mo A, Iadarola M, Holland SM. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012 Aug 23;367(8):725-34. doi: 10.1056/NEJMoa1111160.
Study record dates
Study Major Dates
Study Start (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999909060
- 09-I-N060
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opportunistic Infections
-
Erasmus Medical CenterCompletedHIV/AIDS | Opportunistic Infections, HIV RelatedNetherlands
-
Zhongnan HospitalActive, not recruitingOcular Complications in AIDS Patients, Such as Fundus Opportunistic Infections, Microangiopathy, and UveitisChina
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | AIDS-Related Opportunistic InfectionsUnited States, Puerto Rico, South Africa
-
George Papanicolaou HospitalUniversity General Hospital of PatrasRecruitingBone Marrow Transplant Infection | Opportunistic Fungal Infection | Opportunistic Viral InfectionGreece
-
University of MinnesotaNational Institute of Allergy and Infectious Diseases (NIAID); Mbarara University... and other collaboratorsTerminatedCryptococcosis | AIDS-Related Opportunistic Infections | Cryptococcal InfectionsUganda
-
Elizabeth Glaser Pediatric AIDS FoundationBill and Melinda Gates FoundationActive, not recruitingAIDS-related Kaposi Sarcoma | Cryptococcal Infections | AIDS and Infections | Opportunistic Infections, HIV-Related | AIDS With TuberculosisMalawi
-
National Institute of Allergy and Infectious Diseases...CompletedCommunicable Diseases | Opportunistic InfectionsUnited States
-
Medical University of GrazKrankenhaus der Barmherzigen Bruder Graz; Krankenhaus der Elisabethinen Graz; Landeskrankenhaus Feldbach and other collaboratorsCompletedLaparoscopic Cholecystectomy | Prophylactic Salpingectomy | Opportunistic SalpingectomyAustria
-
Sociedad Española de TrasplanteRoche Farma, S.ACompletedOpportunistic InfectionsSpain
-
National Hospital for Tropical Diseases, Hanoi,...Centers for Disease Control and Prevention; Hospital for Tropical Diseases,...UnknownHIV/AIDS | Mycosis Fungoides | Cryptococcosis | Cryptococcal Meningitis | Opportunistic Infections, HIV Related | Mycosis; OpportunisticVietnam